Estrella Immunopharma, Inc. (ESLA) - Dilution Analysis

S-1/A filing: This prospectus relates to the offer and resale from time to time by the selling stockholders named in this prospectus of up to 9,236,141 shares of our Common Stock.

8-K filing: Estrella Immunopharma, Inc. completed a registered direct offering and concurrent private placement on January 6, 2026, issuing shares of common stock, pre-funded warrants, and common stock purchase warrants, resulting in gross proceeds of approximately $8.0 million.

S-1 filing: This prospectus relates to the offer and resale from time to time by the selling stockholders named in this prospectus of up to 2,541,206 shares of our Common Stock.

10-Q filing | 37.1M shares outstanding

10-Q filing | 36.2M shares outstanding

8-K filing: Estrella Immunopharma, Inc. entered into a securities purchase agreement to issue and sell 2,233,334 shares of common stock at $1.50 per share in a private placement, for gross proceeds of approximately $3.35 million. ($3.35M proceeds)

10-Q filing | 36.2M shares outstanding

S-3 filing: Estrella Immunopharma, Inc. may offer and sell up to $100,000,000 of common stock from time to time.

10-Q filing | 36.2M shares outstanding

10-K filing | 36.2M shares outstanding

10-Q filing | 35.5M shares outstanding

10-Q filing | 35.2M shares outstanding

S-1/A filing: This prospectus relates to the offer, sale and resale from time to time of certain shares of common stock of Estrella Immunopharma, Inc.

10-Q filing | 35.2M shares outstanding

S-1/A filing: This is an S-1/A filing for the offer, sale and resale of common stock of Estrella Immunopharma, Inc., including shares issued in connection with a merger, shares to be issued to White Lion Capital, LLC, and shares issuable upon exercise of warrants.

S-1 filing: This S-1 filing relates to the offer, sale, and resale of common stock, including shares issued pursuant to subscription agreements, shares that may be issued to White Lion Capital, LLC, and shares issuable upon the exercise of warrants.

8-K filing: TradeUP Acquisition Corp. entered into subscription agreements with Plentiful Limited and Lianhe World Limited for the purchase of $5,000,000 shares of the company's common stock at $10.00 per share, contingent on the closing of the Business Combination. ($50.0M proceeds)

10-Q filing | 2.2M shares outstanding

8-K filing: 650,580 shares of common stock were rendered for redemption in connection with the stockholder vote.

8-K filing: TradeUP Acquisition Corp. entered into a binding term sheet with Suma Ventures, LLC, Estrella Biopharma, Inc., and Eureka Therapeutics, Inc., where Suma Ventures will acquire 680,000 Class B units of UPTD (to become New Estrella Units) in exchange for waiving a $6.8 million Indebtedness from Estrella to Eureka.

8-K filing: TradeUP Acquisition Corp. stockholders approved an extension to the liquidation date and charter amendment, leading to the redemption of 161,566 shares of common stock.

10-Q filing | 5.8M shares outstanding

8-K filing: TradeUP Acquisition Corp. amended its Common Stock Purchase Agreement with White Lion Capital, LLC, agreeing to cause Estrella Biopharma, Inc. to issue 250,000 shares of Estrella's Series A preferred stock to White Lion immediately prior to the closing of the proposed business combination with Estrella.

10-K filing | 2.3M shares outstanding

8-K filing: TradeUP Acquisition Corp. issued an unsecured promissory note in the amount of $50,000 to TradeUP Acquisition Sponsor LLC and also issued an unsecured promissory note in the amount of $45,511 to Estrella Biopharma, Inc. Both notes can be converted into common stock at $10.00 per share.

8-K filing: TradeUP Acquisition Corp. extended the date to complete a business combination from January 19, 2023, to July 19, 2023, and 3,519,780 shares of common stock were redeemed in connection with this extension.

10-Q filing | 5.8M shares outstanding

8-K filing: TradeUP Acquisition Corp. entered into a merger agreement with Estrella Biopharma, Inc., where Merger Sub will merge with Estrella Biopharma, and Estrella stockholders will receive UPTD common stock in consideration of converting their shares, with UPTD changing its name to Estrella Immunopharma, Inc. ($325.0M proceeds)

10-Q filing | 1.4M shares outstanding

10-Q filing | 1.4M shares outstanding

10-K filing | 1.4M shares outstanding

10-Q filing | 1.4M shares outstanding

8-K filing: TradeUP Acquisition Corp. consummated an initial public offering of 4,000,000 units at $10.00 per Unit, generating gross proceeds of $40,000,000, and completed private placements of Class A Common Stock generating gross proceeds of $2,950,000 and $172,000 respectively. Underwriters purchased 430,000 Units generating gross proceeds of $4,300,000. ($3.12M proceeds)

8-K filing: The Company completed the private sale of 295,000 Private Placement Shares to the Founders at a purchase price of $10.00 per Private Placement Share, generating gross proceeds to the Company of $2,950,000, and adopted its Amended and Restated Certificate of Incorporation. ($2.95M proceeds)

S-1/A filing: TradeUP Acquisition Corp. is offering 4,000,000 units at $10.00 per unit, each unit consisting of one share of common stock and one-half of one redeemable warrant, in an initial public offering, and is also conducting a private placement of common stock.

S-1/A filing: Initial public offering of 4,000,000 units at $10.00 per unit, each unit consisting of one share of common stock and one-half of one redeemable warrant.

S-1/A filing: TradeUP Acquisition Corp. is offering 4,000,000 units at $10.00 per unit, each consisting of one share of common stock and one-half of one redeemable warrant, in an initial public offering. They are also offering 295,000 shares of common stock in a private placement at $10.00 per share.

S-1/A filing: TradeUP Acquisition Corp. is offering 4,000,000 units at a price of $10.00 per unit, with each unit consisting of one share of common stock and one-half of one redeemable warrant.

S-1/A filing: TradeUP Acquisition Corp. is offering 4,000,000 units at $10.00 per unit, each unit consisting of one share of common stock and one-half of one redeemable warrant, in an initial public offering. Additionally, founders have committed to purchase an aggregate of 215,000 shares of common stock (or up to 227,000 shares of common stock if our underwriters exercise the over-allotment option) at $10.00 per share for a total purchase price of $2,150,000 (or up to $2,270,000 if our underwriters exercise the over-allotment option).

S-1/A filing: This is an S-1/A filing for an initial public offering of units of TradeUP Acquisition Corp., a blank check company, with each unit consisting of one share of common stock and one-half of one redeemable warrant. They are also issuing private shares to founders.

S-1/A filing: TradeUP Acquisition Corp. is offering 4,000,000 units at $10.00 per unit, each consisting of one share of common stock and one-half of one redeemable warrant, in an initial public offering.

S-1/A filing: This S-1/A filing relates to an offering of Common Stock where the net proceeds will be deposited in a trust account and may be used for a business combination or redemption of shares.

S-1/A filing: TradeUP Acquisition Corp. is offering 4,000,000 units at $10.00 per unit, with each unit consisting of one share of common stock and one-half of one redeemable warrant, in an initial public offering.

S-1 filing: TradeUP Acquisition Corp. is offering 4,000,000 units, each consisting of one share of common stock and one-half of one redeemable warrant, in an initial public offering at a price of $10.00 per unit.